119 related articles for article (PubMed ID: 23402559)
1. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization for anemia management: current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A.
Saueressig U; Kwan JT; De Cock E; Sapède C
Blood Purif; 2008; 26(6):537-46. PubMed ID: 18997465
[TBL] [Abstract][Full Text] [Related]
3. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
[No Abstract] [Full Text] [Related]
4. Time Savings with Once-Monthly C.E.R.A.: A Time and Motion Study Conducted in 13 Haemodialysis Centres in Italy.
De Cock E; Kritikou P; Ravera S; Filippini A
Blood Purif; 2015; 40(2):173-9. PubMed ID: 26303977
[TBL] [Abstract][Full Text] [Related]
5. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
7. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
[TBL] [Abstract][Full Text] [Related]
10. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
[TBL] [Abstract][Full Text] [Related]
11. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
12. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
13. Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial.
Forni V; Bianchi G; Ogna A; Salvadé I; Vuistiner P; Burnier M; Gabutti L
BMC Nephrol; 2013 Jul; 14():157. PubMed ID: 23870287
[TBL] [Abstract][Full Text] [Related]
14. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
16. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study.
Kessler M; Martínez-Castelao A; Siamopoulos KC; Villa G; Spinowitz B; Dougherty FC; Beyer U
Hemodial Int; 2010 Apr; 14(2):233-9. PubMed ID: 19888948
[TBL] [Abstract][Full Text] [Related]
17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
18. Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care.
Schiller B; Besarab A
Curr Med Res Opin; 2011 Aug; 27(8):1539-50. PubMed ID: 21682552
[TBL] [Abstract][Full Text] [Related]
19. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population.
Sharma A; Yee J; Gandra SR; Khan I; Petersen J
Curr Med Res Opin; 2010 Nov; 26(11):2679-87. PubMed ID: 20942616
[TBL] [Abstract][Full Text] [Related]
20. Prolonged Duration of Erythropoiesis-Stimulating Agents' Action Delays Disease Progression in Anti-Thy 1 Antibody-Induced Chronic Glomerulonephritis Rats.
Kawasaki R; Tashiro Y; Yogo K; Serizawa K; Aizawa K; Endo K; Hirata M
Pharmacology; 2021; 106(1-2):45-52. PubMed ID: 32829322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]